Arbutus Biopharma Corp (ABUS) · Oct 22, 2026 · Other events
IND hold removed — FDA permits additional U.S. clinical development
Arbutus Biopharma’s FDA update removes the AB-101 clinical hold, but the next U.S. trial and timeline remain undecided.
Arbutus is a clinical-stage HBV biotech trying to build a combination treatment around imdusiran, with AB-101 intended to boost the immune response against chronic hepatitis B. Its broader strategy combines viral suppression, antigen reduction, and immune activation. AB-101 had been blocked by an FDA clinical hold since April 2023, making regulatory clearance the immediate gating issue for the program.
The main overhang is removed. The FDA has lifted the clinical hold and said Arbutus may pursue additional U.S. clinical development for AB-101. 〔0〕 This restores a development path for an asset that had effectively been frozen for more than three years.
This is regulatory permission, not a clinical restart. Arbutus says it is still “evaluating next steps,” with no new study design, start date, dose plan, enrollment target, or development budget disclosed. 〔1〕 The event therefore advances the business meaningfully, but does not yet establish how quickly AB-101 can generate new human data or how much capital the program will require.
The existing signal is encouraging but early. The completed Phase 1a/1b study found AB-101 generally well tolerated, with high receptor occupancy in seven chronic-HBV patients and hepatitis B surface-antigen decline in two patients at 30 mg. Those observations support further testing, but the small patient count and lack of a new efficacy readout leave the drug’s clinical value unproven.
Bottom line: This is a genuinely important unlock for Arbutus’s HBV pipeline because AB-101 can move forward in the United States again. The next value-bearing step is not the hold removal itself, but whether Arbutus commits to a defined trial with a credible timeline and funding plan.
AB-101 U.S. trial plan and timing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!